# OnCo record legend-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/legend-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "legend-2", "NCT03090659" ;
  schema:name "LEGEND-2"@en ;
  schema:description "The small Chinese trial whose startling response rates at ASCO 2017 drew Johnson and Johnson to Legend Biotech and became the myeloma CAR-T Carvykti."@en ;
  schema:url <https://onco.cc/trials/legend-2/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03090659>, <https://doi.org/10.1186/s13045-018-0681-6> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "1/2" ;
  schema:startDate "2015-10-02" ;
  onco:related <https://onco.cc/trials/cartitude-1/>, <https://onco.cc/trials/cartitude-4/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:drugs <https://onco.cc/drugs/ciltacabtagene-autoleucel/> ;
  onco:companies <https://onco.cc/companies/legend-biotech/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:people <https://onco.cc/people/zhang-fangliang/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zhao-j-hematol-oncol/> .